# Secukinumab in Active Non-segmental Vitiligo

> **NCT05676333** · PHASE4 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 8 (actual)

## Conditions studied

- Vitiligo
- Secukinumab

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT05676333
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-12
- **Primary completion:** 2017-12-16
- **Final completion:** 2019-02-22
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05676333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05676333, "Secukinumab in Active Non-segmental Vitiligo". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05676333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*